Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Early look at data for CAR-T bb21217 in R/R MM

bb21217 is a next-generation anti-BCMA CAR T-cell therapy, which has shown promising results for the treatment of relapsed/refractory multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital, Boston, MA, discusses the safety and efficacy of bb21217 from the Phase I dose escalation CRB-402 trial (NCT03274219) that was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.